Sequoia Sciences Receives FDA Fast Track Designation for Vaccine for Urinary Tract Infections Caused by Multidrug-Resistant Bacteria

Non-Antibiotic Treatment Approach May Reduce the Development of Antibiotic Resistance and Promote Antibiotic Stewardship

ST. LOUIS, July 26, 2017 /PRNewswire/ -- Sequoia Sciences announced it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its novel, investigational vaccine designed to treat recurrent urinary tract infections (UTI) caused by multidrug-resistant bacteria. Fast Track Designation expedites the development and review of the vaccine through the U.S. regulatory process.

Sequoia's vaccine is designed to create an immune response preventing bacteria from colonizing the urinary tract, and it recently completed its first clinical trial in women. Of the 67 women enrolled in this first study, 30 had a two-year documented history of recurrent UTI. The vaccine was well-tolerated and generated a strong immune response.1 Based on the results of this first study, initiation of additional studies is ongoing including evaluating Sequoia's vaccine in patients requiring last-line of defense antibiotics. In granting Fast Track status, the FDA acknowledges that recurrent UTI caused by multidrug-resistant bacteria is a serious condition for which there is an unmet medical need.

"If approved, the vaccine could change the standard of care for recurrent UTI," said Gary Eldridge, president and CEO, Sequoia Sciences. "Since UTI are a primary source of sepsis, decreasing recurrent UTI may ultimately drive down rates of hospitalization, sepsis and associated in-hospital mortality."

Recurrent UTI Are Increasing Antibiotic Resistance

Antibiotics are the current standard of care for UTI patients, but repeated antibiotic use in this population contributes to the development of antibiotic resistance. Recurrent UTI patients frequently take daily antibiotics for one to four months or even longer. Each year, approximately 3 million patients in the U.S. and 10 million patients in North America, Europe and Japan experience recurrent UTI.2 It is estimated that about half of these patients have UTI caused by antibiotic-resistant bacteria.3

In a 2010 survey, 83 percent of urologists reported having administered intravenous antibiotics to recurrent UTI patients who were resistant to all available oral antibiotics.4 Antibiotic resistance among UTI patients has continued to increase. The North American Emerging Infections Network reported that about 80 percent of responding infectious disease physicians had treated a UTI caused by the most resistant bacteria, carbapenem-resistant Enterobacteriaceae (CRE).5 Even more alarming, in 2016 CRE among patients in long-term care facilities was found to be more widespread than predicted.6 There are currently no FDA-approved therapies to specifically treat recurrent UTI.

"Many of my patients with multidrug-resistant recurrent urinary tract infections have tried multiple antibiotics for years without success," said Liz D'Antonio, CRNP, director of clinical research Anne Arundel Urology. "A vaccine presents a new approach that could offer new hope for these patients. We eagerly await the results of the next studies as it hopefully moves toward approval."

Antibiotic Resistance — A Global Health Threat

Leading health care organizations, including Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, World Health Organization and Infectious Diseases Society of America (IDSA), have declared that antibiotic resistance is one of the most serious health threats facing the world.7 New rules requiring antibiotic stewardship programs in hospitals emphasize the need to use fewer antibiotics. Sequoia's investigational vaccine, if approved by the FDA, may help reduce the use of antibiotics and address this growing health threat.

About Sequoia Sciences

Sequoia Sciences is a pharmaceutical company discovering and developing new medicines targeting bacterial infections and cancers. Our pipeline includes a vaccine for the treatment and prevention of recurrent urinary tract infections and compounds targeting infection and cancer.

Forward-Looking Statements

Some statements in this news release are, or may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Sequoia Sciences cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.

1 Sequoia Sciences' Annual Report 2016.
2 2014 National Disease and Therapeutic Index (NDTI, IMS Health, Plymouth Meeting, PA). ICD9: 595.0; 595.9; 599.0; 597.8.
3 Sanchez et al. Antibiotic Resistance among Urinary Isolates from Female Outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother. 2016;60(5):2680-3; Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control; 2015.
4 Urologist UTI Survey. Sequoia Sciences, Inc. and HRA Research; 2010.
5 Trevino et al. Perceptions and behaviours of infectious diseases physicians when managing urinary tract infections due to MDR organisms. J Antimicrob Chemother. 2015;70(12):3397-3400.
6 Han et al. Epidemiology of Carbapenem-Resistant Klebsiella Pneumoniae in a Network of Long-Term Acute Care Hospitals. Clinical Infectious Diseases. 2017;64(7):839-44.
7 Ventola CL. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics. 2015;40(4):277-83; World Health Organization Fact Sheets. [cited 2016 November 3]; Available from: http://www.who.int/mediacentre/factsheets/fs194/en/.

 

View original content:http://www.prnewswire.com/news-releases/sequoia-sciences-receives-fda-fast-track-designation-for-vaccine-for-urinary-tract-infections-caused-by-multidrug-resistant-bacteria-300493148.html

SOURCE Sequoia Sciences

Diplomat Now Dispensing VOSEVI(TM) to Treat Chronic Hepatitis C Virus

The nation's largest independent specialty pharmacy is now dispensing VOSEVI(TM) (sofosbuvir, velpatasvir, and voxilaprevir).

FLINT, Mich., July 26, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is now dispensing newly approved VOSEVI™ (sofosbuvir/velpatasvir/voxilaprevir) to treat hepatitis C virus infection.

VOSEVI is used to treat all genotypes of chronic hepatitis C virus infection. It is indicated for adults without cirrhosis (liver disease) or with compensated cirrhosis who have previously been treated with a regimen containing an NS5A inhibitor such as EPCLUSA® (sofosbuvir/velpatasvir); HARVONI® (ledipasvir/sofosbuvir); VIEKIRA PAK or VIEKIRA XR (dasabuvir/ombitasvir/paritaprevir/ritonavir); TECHNIVIE (ombitasvir/paritaprevir/ritonavir); ZEPATIER® (elbasvir/grazoprevir); or DAKLINZA (daclatasvir).

VOSEVI is also indicated for chronic hepatitis C infection with genotype 1a or 3 and previous treatment with a regimen containing SOVALDI® (sofosbuvir) without an NS5A inhibitor.

To learn more about Diplomat's hepatitis program, visit diplomat.is/areas-of-excellence/hepatitis.

VOSEVI is a fixed-dose, combination tablet administered once-daily with food for 12 weeks. It contains sofosbuvir and velpatasvir­, as well as the newly approved voxilaprevir.

"Diplomat is proud to expand its therapy offerings to patients who have been diagnosed with chronic hepatitis C," said Paul Urick, president of Diplomat. "Providing an opportunity to treat patients who have failed current treatment options, this combination tablet is a valuable addition to our product offering."

More than 2.7 million Americans have hepatitis C, according to the Centers for Disease Control and Prevention. Hepatitis C infection becomes chronic in approximately 75–85 percent of cases. Unlike many serious diseases, hepatitis C can be cured with treatment.

Hepatitis C causes liver inflammation. Some people with chronic hepatitis C infection develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly.

VOSEVI is manufactured by Gilead Sciences, Inc. For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

 

View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-now-dispensing-vosevi-to-treat-chronic-hepatitis-c-virus-300494212.html

SOURCE Diplomat Pharmacy, Inc.

Flirtey Continues to Lead Drone Delivery Industry

July Marks The Anniversary of The First FAA-Approved Drone Delivery in the U.S. and The First Autonomous Drone Delivery to a Customer's Home

RENO, Nev., July 26, 2017 /PRNewswire/ -- Flirtey, the world's leading drone delivery service, commemorates its milestones in aviation history as July marks the two-year anniversary of the first ever FAA-approved drone delivery in the United States and the one-year anniversary of the first drone delivery to a customer's home.

On July 17 2015, in collaboration with NASA, Flirtey conducted the first-ever FAA-approved drone delivery when it delivered multiple packages of urgent prescription medication to the Remote Area Medical health clinic in Wise, Virginia. The Virginia General Assembly unanimously passed House Joint Resolution 232 commending Flirtey for the achievement.

Flirtey CEO Matthew Sweeny, Senator Mark Warner and Governor Terry McAuliffe hailed the event the "Kitty Hawk" moment for the drone delivery industry, and Flirtey's historic delivery drone was accepted into the Smithsonian's National Air and Space Museum, which displays the Wright Flyer, the Space Shuttle Discovery, and the first aircraft operated by FedEx.

The following year, on July 22 2016, Flirtey made history again by completing the first autonomous drone delivery to a customer home in collaboration with 7-Eleven, the world's largest convenience retailer, by delivering over-the-counter medicines, food and drinks.

Nevada Governor Brian Sandoval said at the time, "I congratulate Nevada-based company Flirtey on making history yet again – this time by collaborating with the world's largest convenience retailer to complete the first store-to-home drone delivery in Reno, Nevada."

Flirtey continues to pioneer the drone delivery industry, having since launched the world's first commercial pizza-by-drone delivery model in partnership with Domino's Pizza Enterprises, and conducting over a month of regular commercial deliveries to customer homes in the U.S.

"Flirtey's mission is to save lives and change lifestyles by making delivery instant," said Flirtey CEO Matthew Sweeny. "Flirtey continues to pioneer drone delivery – when no other company has managed to secure approvals for regular operations, Flirtey has conducted hundreds of approved drone deliveries to customer homes. Every one of these milestones takes us one step closer to drone delivery to your home."

With more regulatory approvals, partner announcements and customer deliveries coming soon, Flirtey is set to make regular drone deliveries commonplace in the U.S. and around the world.

Footage of deliveries available upon request, photos available here: https://www.dropbox.com/sh/t49h8xm7kbt92n9/AABfwYvd4CqlamFCrCLndj6Ta?dl=0

About Flirtey
Flirtey is the world's leading drone delivery service, with a mission to save lives and change lifestyles by making delivery instant. The startup has worked with NASA and top universities to create the technology and logistics systems for a mass-market drone delivery network. Learn more at www.flirtey.com. The company's landmark achievements have been recognized by New Zealand's Museum of Transport and Technology, as well as the Smithsonian Institution for display at its Air and Space Museum.

Media Contact:
Molly Livingston
molly@flirtey.com
510.898.8220

 

View original content with multimedia:http://www.prnewswire.com/news-releases/flirtey-continues-to-lead-drone-delivery-industry-300494221.html

SOURCE Flirtey

Forge Therapeutics Forms Scientific Advisory Board with World Renowned Antibiotic and Drug Development Experts

SAN DIEGO, July 26, 2017 /PRNewswire/ -- Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, announced today the formation of its Scientific Advisory Board (SAB) with leading experts in microbiology, chemistry and antibiotic drug development.  The Forge SAB will help guide the company's scientific vision and mission to discover and develop novel metalloprotein inhibitors. 

"We are honored that each of these acclaimed researchers and drug developers has agreed to serve on the Forge Scientific Advisory Board," said Zachary A. Zimmerman, CEO of Forge. "Their guidance on our scientific vision will be invaluable as we drive our novel, Gram-negative antibiotic program toward the clinic and identify expansion opportunities for our metalloprotein platform." 

About the Forge SAB

Forge has assembled a strategic advisory board comprised of leading microbiology, chemistry, antibiotic and drug development experts from around the globe. 

  • Michael Barbachyn, Ph.D., co-inventor of the antibiotics linezolid (marketed as Zyvox) and sutezolid, and former director-level contributor to antibacterial discovery at Pharmacia, Pfizer and AstraZeneca.
  • Robert Bonomo, M.D., Chief Medical Service at Louis Stokes Cleveland VA Medical Center, and Professor of Medicine at Case Western Reserve University.
  • Seth Cohen, Ph.D., scientific co-founder of Forge and one of the world's leading authorities on metalloprotein inhibitors; Professor and former Chair of the Department of Chemistry and Biochemistry at the University of California, San Diego.
  • John Rex, M.D., Chief Medical Officer and Director at F2G Ltd. and Chief Strategy Officer at CARB-X, the world's largest public-private partnership devoted to antibacterial preclinical R&D.
  • Karen Joy Shaw, Ph.D., current Chief Scientific Officer of Amplyx Pharmaceuticals and former SVP Biology at Trius Therapeutics leading the microbiology strategy for Tedizolid development; former Antibacterial Team Leader Johnson & Johnson and Schering Plough. 
  • Lynn Silver, Ph.D., was involved in the discovery of the first inhibitors of LpxC, and the development of the antibiotic Invanz at Merck where she held the title of senior investigator.
  • Brad Spellberg, M.D., Chief Medical Officer, LA+USC Medical Center and antibiotic resistance expert.
  • Andrew Tomaras, Ph.D., Vice President and Director of Microbiology at BacterioScan Inc. and former LpxC program leader at Pfizer.
  • Mark Whittaker, D.Phil., SVP Drug Discovery at Evotec and former Director Medicinal Chemistry at British Biotech.

About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical company developing novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic.  With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes.  Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow.  Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious in vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.'  To complement its innovative approach to drug discovery, Forge has a capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance its programs, including LpxC.  Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic including CARB-X.  In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline.  For further information, please visit the company's website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.

Forge Company Contact:
Info@ForgeTherapeutics.com

Forge Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

 

View original content with multimedia:http://www.prnewswire.com/news-releases/forge-therapeutics-forms-scientific-advisory-board-with-world-renowned-antibiotic-and-drug-development-experts-300494171.html

SOURCE Forge Therapeutics, Inc.

Innovative PBM Introduces Pharmacogenetics Offering

BeneCard PBF Launches BenePrecise to Eliminate Trial and Error in Finding Medications That Work

MECHANICSBURG, Pa., July 26, 2017 /PRNewswire/ -- BeneCard PBF, a leader in providing clinical solutions that address the crisis of rising drug costs, has taken a step toward more efficient, personalized clinical care for members through its BenePrecise Pharmacogenetics program. Pharmacogenetics allows prescribers and pharmacists to understand how medications react differently in the body based on an individual's metabolism. BenePrecise applies the results of a fast and easy-to-administer pharmacogenetics test to enhance member safety, improve treatment outcomes and prevent wasteful drug spending.

BenePrecise utilizes precision medicine, which evaluates and considers a patient's metabolism, environment and lifestyle, to develop effective, individualized treatment plans. Through BenePrecise, BeneCard PBF's pharmacists work with members and their prescribers to coordinate changes in drug therapies, as indicated by pharmacogenetic testing. This ensures that members receive the most clinically appropriate and effective medications. By proactively identifying which drug therapies will not work, or are likely to cause severe adverse reactions, clients and their members can avoid unnecessary risks and expenses.

"We are excited to offer our BenePrecise program," says Jennifer Fuhrmann, PharmD and Vice President of Clinical Services for BeneCard PBF. "Pharmacogenetic testing can have a measurable positive impact for members who live with chronic health challenges such as diabetes or high cholesterol. Our pharmacists can help them move quickly onto the most appropriate drug therapy and improve their health with fewer side effects and less risk, based on their unique metabolism."

There are no doctor's visits required to administer the test. Members can collect and submit the sample from home using a simple cheek swab. The markers identified by pharmacogenetic testing do not change over a member's lifetime, so repeat tests are not required.

BenePrecise enables a personalized approach to care aimed at reducing costs, improving treatment efficacy and preventing adverse drug reactions.                       

About BeneCard PBF
Through pharmacogenetics and proactive clinical programs, BeneCard PBF enhances patient outcomes while lowering prescription drug costs. With offices in Florida, Pennsylvania and New Jersey, BeneCard PBF administers fixed-rate and self-funded prescription benefit programs. The company offers innovative solutions to control costs while providing the highest quality service available in prescription benefit management.

View original content:http://www.prnewswire.com/news-releases/innovative-pbm-introduces-pharmacogenetics-offering-300494187.html

SOURCE BeneCard PBF

USMD Earns National Recognition for Providing Patient-Centered Care

The National Committee for Quality Assurance Patient Centered Medical Home Program Recognizes 27 USMD Primary Care Clinics

IRVING, Texas, July 26, 2017 /PRNewswire/ -- USMD Holdings, Inc., a physician-led integrated health care system, announced that each of its 27 primary care clinics received recognition as a level 3 Patient Centered Medical Home (PCMH).

Part of the National Committee for Quality Assurance (NCQA), the PCMH program recognizes primary care clinics that successfully demonstrate and use evidence-based, patient-centered processes that focus on highly coordinated patient care, long-term patient relationships and patient-physician partnerships. USMD received level 3 recognition—the highest level attainable—and the designation is valid for three years. This is the third three-year NCQA PCMH designation achieved by USMD primary care clinics.

The PCMH program emphasizes a care delivery model in which treatment is coordinated through patients' primary care physicians to ensure patients understand their care options and decisions, and receive the necessary care when and where they need it. The program focuses on coordination and communication between patients and primary care physicians in an effort to transform primary care into the best experience possible for patients. It also identifies and encourages practices that promote partnerships between patients and their physicians. Instead of treating patients with several episodic office visits, each patient's care is managed by a physician-led team that provides all health care needs and coordinates treatment across a health care system – thus helping patients achieve and maintain good health.

"The Patient Centered Medical Home Program transforms primary care into what patients want and need it to be. Research has shown that medical homes can lead to higher-quality care and lower overall health care costs while improving patients' and care providers' satisfaction and experiences," said Richard C. Johnston, M.D., chief executive officer and chief physician officer of USMD. "We are grateful for the recognition we have received from the PCMH Program. Our clinics and employees share USMD's commitment to ensuring our patients receive quality, effective and compassionate care."

NCQA standards are aligned with the joint principles of the Patient Centered Medical Home established with the American College of Physicians, the American Academy of Family Physicians, the American Academy of Pediatrics and the American Osteopathic Association. To earn PCMH recognition, primary care clinics must successfully demonstrate the ability to meet the program's key elements, which include:

  • Patient-centered access: Accommodate patients' needs during office hours and after, and provide medical home information to patients.
  • Team-based care: Provide team-based care, engage all practice team members and meet patients' cultural and linguistic needs.
  • Population health management: Collect and use data for population health management.
  • Care management and support: Use evidence-based guidelines for preventive, acute and chronic care management.
  • Care coordination and care transitions: Track and coordinate tests, referrals and care transitions.
  • Performance measurement and quality improvement: Use performance and experience data for continuous improvement.

"Our PCMH recognition affirms that we are providing the right care at the right time and in the right setting. We will continue to focus on providing high-quality, highly coordinated and efficient care to patients across the Dallas Fort Worth Metroplex," said Dr. Johnston.

To learn more about USMD, visit www.USMDinc.com.

About USMD Holdings, Inc.
USMD is a physician-led, integrated health system committed to exemplary patient care. Headquartered in Irving, Texas, USMD is part of OptumCare and serves the Dallas-Fort Worth metropolitan area with more than 250 physicians and associate practitioners, and provides health care services to patients in more than 20 different specialties at its two hospitals, one cancer treatment center and nearly 50 physician clinics, many of which are multi-specialty. All 27 of USMD's primary care clinics have been accredited by the Patient Centered Medical Home Program, a recognition program that is part of the National Committee for Quality Assurance. This recognition means that USMD's primary care clinics successfully display and utilize evidence-based, patient-centered processes that focus on highly coordinated patient care and long-term patient relationships. For more information about USMD, visit www.USMDinc.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/usmd-earns-national-recognition-for-providing-patient-centered-care-300492900.html

SOURCE USMD Holdings, Inc.

Roche launches the AVENIO Millisect System for precise and efficient dissection of tissue biopsies

- AVENIO Millisect System utilizes an automated, digitally assisted process to reliably and efficiently isolate clinically relevant cells for diagnostic testing- Efficient tissue dissection maximizes medical value for downstream applications such as sequencing and other molecular methods- Study suggests the AVENIO Millisect System helped reduce false negative results and case rejection rates[1]

PLEASANTON, Calif., July 26, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the AVENIO Millisect System, a tissue dissection instrument that utilizes an automated digitally assisted process to reliably and efficiently isolate clinically relevant cells from formalin-fixed paraffin-embedded (FFPE) tissue slides.

The AVENIO Millisect System addresses challenges inherent in today's tissue dissection practice in the clinical lab workspace where manual dissection lacks consistency and precision, and laser capture microscopy is cumbersome and costly. "We recognize that streamlining and optimizing the pre-analytical workflow is key to obtaining accurate results from complex testing methods such as next generation sequencing," said Neil Gunn, Head of Roche Sequencing Solutions. "The introduction of the AVENIO Millisect System further exemplifies our commitment in creating a simplified workflow that delivers maximal medical value to clinicians and patients."

In a study published in Cancer Genetics1, sequencing samples prepared with the AVENIO Millisect System identified mutations from 7 out of 32 (22%) pancreatic cancer tissues samples that were otherwise missed by manual dissection. The study further suggests that the technology helped reduce false negative results and case rejection rates associated with low tumor content, thereby enabling efficient use of precious tissue samples.

"We believe the AVENIO Millisect System offers a much better means to dissect the component that is most relevant for diagnostic testing," said Dr. Bryan Lo, Director of the Molecular Oncology Diagnostics Laboratory in The Ottawa Hospital. "The AVENIO Millisect System allows us to precisely isolate tumor component from our FFPE tissue specimens in a standardized efficient workflow."

The AVENIO Millisect System is an IVD labeled medical device and is now available in the U.S. and countries accepting the CE mark.

1Geiersbach et al 2016. Cancer Genetics 209:42-49.

About the AVENIO Millisect System

The AVENIO Millisect System is an automated high-performance FFPE tissue dissection system that can help extract the most clinically relevant information from every sample with maximum efficiency. Optimized to fit easily into a variety of clinical workflow configurations, the AVENIO Millisect System allows precise and consistent recovery of regions of interest for molecular pathology, improving the results of diagnostic testing by reducing false-negatives and allowing identification of additional potential therapeutic targets. The AVENIO product line of NGS solutions from Roche will include instruments, assays, reagents and software that aim to make sequencing simple and accessible. For more information, please visit sequencing.roche.com

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

 

View original content:http://www.prnewswire.com/news-releases/roche-launches-the-avenio-millisect-system-for-precise-and-efficient-dissection-of-tissue-biopsies-300494301.html

SOURCE Roche

Prevea Health Partners With DocASAP to Improve Access to Care, Increase Quality and Close Gaps in Care

Wisconsin Health System Will Utilize Online Appointment Scheduling to Connect Patients, Providers and Payors More Effectively

NEW YORK, July 26, 2017 /PRNewswire/ -- DocASAP today announced Prevea Health will utilize its online appointment scheduling solution to connect patients and providers more efficiently to large payors. This innovative healthcare collaboration will utilize DocASAP, the leading online appointment scheduling solution for patient access and engagement, to allow members to book appointments directly with providers at Prevea Health. This connection will enable Prevea Health to improve quality, close gaps in care and improve access to care.

"We are excited to be a part of this unique opportunity to improve the quality of healthcare," said Dr. Ashok Rai, president and CEO at Prevea Health. "As a health system with a passion for delivering excellence in care, we know that this collaborative initiative will simplify the path to care for our patients. By seamlessly connecting providers to insurance providers, Prevea Health is a pioneer in closing gaps in care."

As part of this partnership, DocASAP is aligning with major payors on providing health systems the ability to:

  • Attract more patients through new channels and leverage existing member touch points.
  • Demonstrate the success of improved patient access and scheduling.
  • Create a positive member/patient experience to drive member/patient satisfaction and retention.

"Prevea Health has always looked for technology to solve some of our challenges, such as delivering health care in a rural setting. DocASAP will allow us to intelligently match our patients with providers to help manage population health in our rural markets. Through this new partnership, we will provide our patients with a more efficient way of improving access and reducing quality gaps," said Dr. Paul Pritchard, vice president and chief quality officer, at Prevea Health.

"Our main goal in partnering with major health insurance companies is to improve the access and engagement problem that faces America's healthcare constituents. By enabling our online appointment scheduling solution through payors' member touch-points, we are reducing the hundreds of thousands of phone calls yearly between payors and providers and freeing up valuable administrative resources and time," said Jordan Pisarcik, vice president of accounts and business development, DocASAP. "Through this innovative program that is unique in the healthcare industry, patients will see an improvement in the quality of their healthcare and their lives."

About Prevea Health

Prevea Health's mission is to care for people with passion, pride, and respect. Founded in 1996, Prevea Health partners with HSHS St. Vincent Hospital and HSHS St. Mary's Hospital Medical Center in Green Bay, HSHS St. Nicholas Hospital in Sheboygan, HSHS St. Clare Memorial Hospital in Oconto Falls, HSHS Sacred Heart Hospital in Eau Claire and HSHS St. Joseph's Hospital in Chippewa Falls, to provide access to more than 200 physicians in more than 60 specialty areas. Prevea has more than 40 locations throughout Northeast Wisconsin and Western Wisconsin's Chippewa Valley region. For more information, visit www.prevea.com.

About DocASAP

DocASAP connects patients with optimal care providers by intelligently matching patient needs with care delivery workflows through online appointment scheduling. Through active engagement and robust analytics, healthcare providers can reduce no-shows and drive smarter operational behavior in patient access. DocASAP continues to build value for its clients through many partnerships including UnitedHealthcare and Optum. Established in 2012, the company currently connects healthcare providers with patients, managing millions of appointments each year. For more information, visit our website and our blog.

View original content with multimedia:http://www.prnewswire.com/news-releases/prevea-health-partners-with-docasap-to-improve-access-to-care-increase-quality-and-close-gaps-in-care-300493885.html

SOURCE DocASAP

The Galien Foundation Debuts 2017 Prix Galien USA Nominees in “Best Biotechnology Product,” “Best Pharmaceutical Product,” and “Best Medical Technology” Categories

Winners will be Announced and Recognized by Committee of Distinguished Scientific Leaders on October 26, 2017 at the Prix Galien USA Awards Ceremony

NEW YORK, July 26, 2017 /PRNewswire/ -- The Galien Foundation announced today the 2017 11th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.

"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."

The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.

Best Biotechnology Product (Nominees)

Alexion Pharmaceuticals Inc.

Kanuma®

Alexion Pharmaceuticals Inc.

Strensiq®

Amgen Inc.

IMLYGIC®

Amgen Inc.

Repatha®

Biogen & Ionis Pharmaceuticals

SPINRAZA™

Boehringer Ingelheim

Praxbind®

Eli Lilly and Company

CYRAMZA®

Eli Lilly and Company

LARTRUVO™

Genentech, a Member of the Roche Group

Kadcyla®

GlaxoSmithKline plc

Benlysta®

Merck & Co., Inc.

Zinplava™

Onyx Pharmaceuticals Inc. & Amgen Inc.

Blincyto®

Pfizer Inc.

Trumenba®

Regeneron and sanofi

PRALUENT®

Sarepta Therapeutics, Inc.

EXONDYS 51™

 

Best Pharmaceutical Agent (Nominees)

AbbVie Inc.

Duopa™

AbbVie Inc.

Technivie™

AbbVie Inc.

Venclexta™

ACADIA Pharmaceuticals Inc.

NUPLAZID®

Allergan, Inc.

Dalvance®

Allergan, Inc.

Kybella®

Allergan, Inc.

Viberzi™

Astellas

Cresemba®

AstraZeneca

Lynparza®

AstraZeneca

Tagrisso®

Boehringer Ingelheim

Jardiance®

Boehringer Ingelheim

OFEV®

Bristol-Myers Squibb Company

Daklinza™

Eisai Inc.

Halaven®

Eisai Inc.

Lenvima®

Endoceutics, Inc.

Intrarosa™

Genentech, a Member of the Roche Group

Alecensa®

Genentech, a Member of the Roche Group

Esbriet®

Gilead

Harvoni®

Helsinn Therapeutics Inc. & Eisai Inc.

Akynzeo®

Iroko Pharmaceuticals, LLC

Vivlodex™

Janssen Pharmaceutical Companies

DARZALEX™

Janssen Pharmaceutical Companies

YONDELIS®

Jazz Pharmaceuticals

Defitelio®

LEO Pharma Inc.

Enstilar®

Merck & Co., Inc.

Zepatier®

Novartis

ZYKADIA®

Otsuka Pharmaceutical Co., Ltd.

Rexulti®

Pfizer Inc.

XELJANZ®

Pfizer Inc. and Astellas

Xtandi®

Shire plc

Xiidra®

The Medicines Company

Orbactiv®

UCB, Inc.

Briviact®

Valeant

Jublia®

 

Best Medical Technology (Nominees)

Abbott

CardioMEMS™ HF System

Allergan, Inc.

Juvederm Volbella® XC

Biosense Webster

The THERMOCOOL SMARTTOUCH®, THERMOCOOL
SMARTTOUCH® Surround Flow Catheters and The CARTO
SMARTTOUCH™ Software Module   

Boston Scientific

SpyGlass DS™ Direct Visualization System

Boston Scientific

WATCHMAN™ Left Atrial Appendage Closure Device

BrainScope Company, Inc.

BrainScope® One

INSIGHTEC

Exablate Neuro

Integra LifeSciences

Omnigraft™ Dermal Regeneration Matrix

Johnson & Johnson - DePuy Synthes

ATTUNE® Knee System

Johnson & Johnson - Ethicon

EVARREST® Fibrin Sealant Patch

Koning Corporation

Koning Breast CT 1000

 

"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation.  "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."

The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.  Registration to attend the 2017 Prix Galien USA Awards Ceremony can be accessed here.

Prix Galien Awards Committee 2017

Pr Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

Pr Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA

Pr Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Pr Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT

Pr Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT

Pr Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC

Pr Rebecca RICHARDS-KORTUM,
Ph.D. Professor of Bioengineering, Malcolm Gillis University, Houston, TX

Pr Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Ventures, Cambridge, MA

Pr Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

Pr Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA

Pr P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc. Committee Chairman

About The Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
giana.gregga@finnpartners.com

View original content with multimedia:http://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2017-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300494168.html

SOURCE The Galien Foundation

The Galien Foundation Debuts 2017 Prix Galien USA Nominees in “Best Biotechnology Product,” “Best Pharmaceutical Product,” and “Best Medical Technology” Categories

Winners will be Announced and Recognized by Committee of Distinguished Scientific Leaders on October 26, 2017 at the Prix Galien USA Awards Ceremony

NEW YORK, July 26, 2017 /PRNewswire/ -- The Galien Foundation announced today the 2017 11th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.

"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."

The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.

Best Biotechnology Product (Nominees)

Alexion Pharmaceuticals Inc.

Kanuma®

Alexion Pharmaceuticals Inc.

Strensiq®

Amgen Inc.

IMLYGIC®

Amgen Inc.

Repatha®

Biogen & Ionis Pharmaceuticals

SPINRAZA™

Boehringer Ingelheim

Praxbind®

Eli Lilly and Company

CYRAMZA®

Eli Lilly and Company

LARTRUVO™

Genentech, a Member of the Roche Group

Kadcyla®

GlaxoSmithKline plc

Benlysta®

Merck & Co., Inc.

Zinplava™

Onyx Pharmaceuticals Inc. & Amgen Inc.

Blincyto®

Pfizer Inc.

Trumenba®

Regeneron and sanofi

PRALUENT®

Sarepta Therapeutics, Inc.

EXONDYS 51™

 

Best Pharmaceutical Agent (Nominees)

AbbVie Inc.

Duopa™

AbbVie Inc.

Technivie™

AbbVie Inc.

Venclexta™

ACADIA Pharmaceuticals Inc.

NUPLAZID®

Allergan, Inc.

Dalvance®

Allergan, Inc.

Kybella®

Allergan, Inc.

Viberzi™

Astellas

Cresemba®

AstraZeneca

Lynparza®

AstraZeneca

Tagrisso®

Boehringer Ingelheim

Jardiance®

Boehringer Ingelheim

OFEV®

Bristol-Myers Squibb Company

Daklinza™

Eisai Inc.

Halaven®

Eisai Inc.

Lenvima®

Endoceutics, Inc.

Intrarosa™

Genentech, a Member of the Roche Group

Alecensa®

Genentech, a Member of the Roche Group

Esbriet®

Gilead

Harvoni®

Helsinn Therapeutics Inc. & Eisai Inc.

Akynzeo®

Iroko Pharmaceuticals, LLC

Vivlodex™

Janssen Pharmaceutical Companies

DARZALEX™

Janssen Pharmaceutical Companies

YONDELIS®

Jazz Pharmaceuticals

Defitelio®

LEO Pharma Inc.

Enstilar®

Merck & Co., Inc.

Zepatier®

Novartis

ZYKADIA®

Otsuka Pharmaceutical Co., Ltd.

Rexulti®

Pfizer Inc.

XELJANZ®

Pfizer Inc. and Astellas

Xtandi®

Shire plc

Xiidra®

The Medicines Company

Orbactiv®

UCB, Inc.

Briviact®

Valeant

Jublia®

 

Best Medical Technology (Nominees)

Abbott

CardioMEMS™ HF System

Allergan, Inc.

Juvederm Volbella® XC

Biosense Webster

The THERMOCOOL SMARTTOUCH®, THERMOCOOL
SMARTTOUCH® Surround Flow Catheters and The CARTO
SMARTTOUCH™ Software Module   

Boston Scientific

SpyGlass DS™ Direct Visualization System

Boston Scientific

WATCHMAN™ Left Atrial Appendage Closure Device

BrainScope Company, Inc.

BrainScope® One

INSIGHTEC

Exablate Neuro

Integra LifeSciences

Omnigraft™ Dermal Regeneration Matrix

Johnson & Johnson - DePuy Synthes

ATTUNE® Knee System

Johnson & Johnson - Ethicon

EVARREST® Fibrin Sealant Patch

Koning Corporation

Koning Breast CT 1000

 

"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation.  "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."

The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.  Registration to attend the 2017 Prix Galien USA Awards Ceremony can be accessed here.

Prix Galien Awards Committee 2017

Pr Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

Pr Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA

Pr Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Pr Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT

Pr Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT

Pr Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC

Pr Rebecca RICHARDS-KORTUM,
Ph.D. Professor of Bioengineering, Malcolm Gillis University, Houston, TX

Pr Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Ventures, Cambridge, MA

Pr Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

Pr Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA

Pr P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc. Committee Chairman

About The Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
giana.gregga@finnpartners.com

View original content with multimedia:http://www.prnewswire.com/news-releases/the-galien-foundation-debuts-2017-prix-galien-usa-nominees-in-best-biotechnology-product-best-pharmaceutical-product-and-best-medical-technology-categories-300494168.html

SOURCE The Galien Foundation